Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma
新型口服PI3Kα/δ抑制剂TQ-B3525治疗复发和/或难治性滤泡性淋巴瘤的II期研究
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-024-01798-0
Wang, Huaqing; Feng, Jifeng; Liu, Yanyan; Qian, Zhengzi; Gao, Da; Ran, Xuehong; Zhou, Hui; Liu, Lihong; Wang, Binghua; Fang, Meiyun; Zhou, Hebing; Huang, Zhenqian; Tao, Shi; Chen, Zhuowen; Su, Liping; Su, Hang; Yang, Yu; Xie, Xiaobao; Wu, Huijing; Sun, Ping; Hu, Guoyu; Liang, Aibin; Li, Zhiming
